Join Meredith Landry, Managing Editor of Citeline’s Custom Content, in conversation with Tom Hickey, Director of Therapeutic Strategy at Novotech, a global full-service clinical CRO dedicated to accelerating the development of advanced and novel therapeutics. In this episode, recorded at the annual BIO conference in Boston, Tom offers a sharp and timely look at the state of RNA therapeutics and shares how innovation in delivery technologies, regulatory strategy, and partnership models is shaping the next generation of RNA-based medicines. With Novotech’s deep experience in the space, Tom provides actionable insights for biotech leaders looking to position their RNA programs for long-term success.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related